Skip to main content
Original source: Kodiak Sciences Inc.·Distribution channel: Commercial newswire·US·

Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...

Short extract only — this publisher licenses its text. Read the full release at the source.

More from Commercial newswire

The rest of this wire is for subscribers

Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.

7 days, no card required.

Read releases like this the second they cross the wire.

1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.

Start the free trial →

Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.

PPN Source →
Shared via PPN World — real-time press release intelligence.